[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350386-105":59,"doc-detail-350386-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","invasive-ductal-and-lobular-carcinoma-and-receptor-status-in-the-genetic-context-of-breast-cancer","Invasive ductal and lobular carcinoma and receptor status in the genetic context of breast cancer","","Retrospective chart review analyzes patients diagnosed with invasive lobular carcinoma (ILC) or invasive ductal carcinoma (IDC) who carry germline breast cancer predisposition mutations. From 372 patients, 88.4% had IDC and 11.6% had ILC; tumor grade and receptor status were assessed. Results identify stronger associations of ILC with variants in ATM, BRCA2, CDH1, CHEK2, EPCAM, PALB2, and PMS2, alongside distinct clinical features and hormone receptor patterns. Findings support tailored genetic counseling and emphasize ILC’s distinctive traits independent of genetic backdrop.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/invasive-ductal-and-lobular-carcinoma-and-receptor-status-in-the-genetic-context-of-breast-cancer/350386/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/invasive-ductal-and-lobular-carcinoma-and-receptor-status-in-the-genetic-context-of-breast-cancer/350386.png","ImageObject",300,407,{"name":92,"@type":93},"McQueen","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What patient groups were included in the study?","Question",{"text":112,"@type":113},"Patients diagnosed with either ILC or IDC and a germline mutation predisposing to breast cancer were included. Individuals with other primary cancers and breast cancers that were neither IDC nor ILC were excluded.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did the genetic mutation profile relate to ILC versus IDC?",{"text":117,"@type":113},"Several variants, including ATM, BRCA2, CDH1, CHEK2, EPCAM, PALB2, and PMS2, were more strongly associated with ILC compared with IDC, with some genes less commonly found in ILC patients.",{"name":119,"@type":110,"acceptedAnswer":120},"What receptor status differences were reported for ILC patients?",{"text":121,"@type":113},"ILC tumors showed hormone receptor-positive patterns and HER2-negative status more often than ductal tumors, including higher estrogen receptor positivity and progesterone positivity with HER2 negativity.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350386,1790323833,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},5909890329169,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nInvasive ductal and lobular carcinoma and receptor status in the genetic context of breast cancer  \nMahmoud Al-Masri1,2􀀍, Osama Alayyan3 & Yasmin Safi1  \nInvasive lobular carcinoma (ILC) represents about 10% of invasive breast cancers and is increasingly considered a unique disease entity. Certain genetic mutations predispose patients to ILC, as such this study aims to explore the ILC and IDC (invasive ductal carcinoma) in a genetic context. This  \nis a retrospective chart review study. Any patient diagnosed with either ILC or IDC and a germline mutation with a predisposition for breast cancer is included in the study. Data was analyzed by patient’s demographics, group stage, family history, and genetic mutation. Additionally, each tumor was analyzed for grade and receptor status. This study reviewed 372 patients of which 88.4% had IDCand 11.6% had ILC. Our results indicate that several variants in ATM, BRCA2, CDH1, CHEK2, EPCAM, PALB2, and PMS2 are more strongly associated with ILC-to varying degrees. [p \u003C 0.001]. Additionally, ILC tumors kept several characteristics, even in the genetic context. ILC patients had a higher median age at presentation [p = 0.043], were more likely to have a lower grade compared to ductal tumors [p \u003C 0.001]. and be estrogen receptor positive [p \u003C 0.001] progesterone status positive [p \u003C 0.001] and HER2 negative [p = 0.043]. ILC patients are more likely to have certain genetic mutations over others. This can help clinicians adapt when counseling these patients. Furthermore, ILC keeps its distinctive characteristics independent of the genetic backdrop.  \nKeywords Invasive lobular carcinoma, Invasive ductal carcinoma, Genetic predisposition, Breast cancer genetics, Hormone receptors, HER2-receptor  \nSeveral cancers have a heritable component, including breast cancer. In the era of genetic testing several pathogenic variants have been identified and linked to an increased risk of developing breast cancer. Among the identified mutations are Breast Cancer susceptibility genes type 1 and type 2 (BRCA1 and BRCA2) and Partner and Localizer ofBRCA2 (PALB2)1.  \nCarrying one of these mutations has certain implications for patients, such as modified screening strategies, risk-reducing surgery or potential use of targeted therapeutic agents2,3. Certain mutations can also predispose women to potentially different invasive pathologies, namely invasive ductal carcinoma (IDC) or invasive lobular carcinoma (ILC)3. Beyond histological subtype, genetic mutations may affect breast cancer phenotype, including receptor expression (6). While histological subtype alone should not determine genetic testing eligibility, clinical and pathological information provides a more robust basis to inform therapeutic decisions2,5.  \nIt is additionally important to consider that ILC can be regarded as a molecularly and epidemiologically different disease from IDC6. For example, ILC normally presents at a later age, and the risk of developing ILCis more strongly related to menopausal hormone therapy compared to other invasive breast cancer subtypes6. Furthermore, ILC and IDC have different risk factors, further distinguishing etiologic pathways7. Considering that ILC is increasingly being considered a unique disease entity, and since genetic mutations have an established influence on breast cancer subtypes, exploring the differences between ILC and IDC in terms of molecularity within genetic context is of significant value and can lead way to further distinguishing these two entities.  \n1Department of Surgery, King Hussein Cancer Center, Amman, Jordan. 2University of Jordan, Amman, Jordan.  \n3Office of Scientific Affairs and Research, King Hussein Cancer Center, Amman, Jordan. 􀀍 [email: malmasri@khcc.jo](email: malmasri@khcc.jo)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nResults  \n8856 patients were diagnosed with breast ca","cbCaivdZrmSSrKBD","https://ap.wps.com/l/cbCaivdZrmSSrKBD","pdf",1645861,"English","# Results\n## Study population and inclusion criteria\n## Clinical and pathological differences between ILC and IDC\n## Age distribution by genetic mutation\n## Tumor type distribution by genetic mutation\n## Receptor status patterns across mutations","[{\"question\":\"What patient groups were included in the study?\",\"answer\":\"Patients diagnosed with either ILC or IDC and a germline mutation predisposing to breast cancer were included. Individuals with other primary cancers and breast cancers that were neither IDC nor ILC were excluded.\"},{\"question\":\"How did the genetic mutation profile relate to ILC versus IDC?\",\"answer\":\"Several variants, including ATM, BRCA2, CDH1, CHEK2, EPCAM, PALB2, and PMS2, were more strongly associated with ILC compared with IDC, with some genes less commonly found in ILC patients.\"},{\"question\":\"What receptor status differences were reported for ILC patients?\",\"answer\":\"ILC tumors showed hormone receptor-positive patterns and HER2-negative status more often than ductal tumors, including higher estrogen receptor positivity and progesterone positivity with HER2 negativity.\"}]","Invasive ductal and lobular carcinoma and receptor status in the genetic context of breast cancer | PDF",1790088816,18,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0880256cc8c56f30294db746d9655684.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f38c3e430289c204a07be7d607352db6.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/371b49f8646d31adca8f43f5d3dcdea5.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d92144b33858e71869403886480465a1.webp",980,1287]